每经AI快讯,3月17日,石药集团公众号消息,近日,由石药集团李春雷博士、苏晓晔博士,以及复旦大学甘建华教授作为共同通讯作者,祁思娴博士作为第一作者合作完成的一项关于基因编辑治疗转甲状腺素蛋白淀粉样变(ATTR)的研究成果,以研究论文形式发表在国际著名权威期刊 Science Advances 。该研究系统性探究了高保真SpCas9突变体在ATTR治疗中的应用,为推动相关疗法的临床转化提供了...
Source Link每经AI快讯,3月17日,石药集团公众号消息,近日,由石药集团李春雷博士、苏晓晔博士,以及复旦大学甘建华教授作为共同通讯作者,祁思娴博士作为第一作者合作完成的一项关于基因编辑治疗转甲状腺素蛋白淀粉样变(ATTR)的研究成果,以研究论文形式发表在国际著名权威期刊 Science Advances 。该研究系统性探究了高保真SpCas9突变体在ATTR治疗中的应用,为推动相关疗法的临床转化提供了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.